Themis bags vaccine licenseVienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to … more ➔
Medivation opens books to SanofiCalifornian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist … more ➔
Next chapter in Dx IP disputeThe European Commission started an investigation into Illuminas and Sequenoms 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive … more ➔
Cinfa shows biosimilar equivalenceCinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers … more ➔
An X-ray look at GPCR structureUKs Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find … more ➔
Partnership targets leukaemiaNordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody. more ➔
Biotech responds to Brexit voteAfter the British people voted in favour of leaving the European Union, the industry is grappling with the profound impact this will likely have on the economy, research and politics. Representatives … more ➔
Malin hauls in €70m from EIBUK investment vehicle Malin has secured another €70m to invest in innovation and research across the European life sciences. The European Investment Bank will provide a debt facility over a period … more ➔
TxCell licenses CAR-T techTxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Sciences tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered … more ➔
Cat allergy setback for CircassiaCircassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The companys shares, listed in London, plunged to a third of its previous … more ➔
